Marker Therapeutics Inc (MRKR)

[guydiamond]

EDIT: sorry for the double post, ran out of time to update previous message

I was thinking the same. Catherine Bollard looks to be part of the same group that originated the technology:

https://www.google.com/search?q=bollard+leen+vera+heslop+rooney

Most have ended up with Marker / Viracyte, but not Bollard for some reason - maybe because she's not from Baylor?

Her trial, TAA-T,

https://clinicaltrials.gov/ct2/show/NCT03843294 https://clinicaltrials.gov/ct2/show/NCT02203903 (both P1, primary completion 2023)

targets Hodgkin's and DLBCL with WT1/PRAME/Survivin in combination with an anti PD1 checkpoint inhibitor, and then AML with the same antigens.

Whereas the MultiTAA trial,

https://clinicaltrials.gov/ct2/show/NCT01333046?term=multitaa&rank=4 https://clinicaltrials.gov/ct2/show/NCT02494167?term=multitaa&rank=2 (P1, primary completion 2019 and 2021)

targets Hodgkin's and non Hodgkin's lymphoma with PRAME/SSX/MAGE/NY-ESO/Survivin as a stand alone therapy, and then AML with PRAME/NY-ESO1/WT1/Survivin as adjuvant to stem cell transplant and as stand alone.

It does seem like the checkpoint inhibitor combination might have very good potential, and I wondered if Marker would be running a trial arm with it.

Either way, I wonder if the TAA-T trial would be complementary or competitive with Marker's pipeline. At the very least, if the TAA-T trial has significant efficacy, that would be some indication of MultiTAA performance with a checkpoint inhibitor.

Thoughts?